Monitor for further details on the LightSolver acquisition structure, including the number of closing shares and warrant terms, as well as any strategic alternative outcomes for the legacy biotech assets. The 2028 commercial target for the LPU platform means near-term revenue is unlikely.
Price Chart
Executive Summary
CollPlant Biotechnologies hosted an investor webinar on September 17, 2026, announcing its acquisition of LightSolver, an optical computing company, and posted an updated corporate presentation. The presentation details LightSolver's all-optical LPU technology for high-performance computing, a $5M funding commitment at closing, and warrant tranches tied to milestones, while noting CollPlant continues to evaluate strategic alternatives for its existing biotech assets. The filing is a routine 6-K furnishing a corporate presentation and contains no financial results or binding transaction terms.
Key Facts
- CollPlant announced the acquisition of LightSolver, an all-optical computing company, via an investor webinar on September 17, 2026.
- At closing, CollPlant will issue closing shares and pre-funded warrants, and provide $5M in funding to LightSolver.
- Warrant tranches are tied to specified technology and commercial milestones.
- CollPlant continues to evaluate strategic alternatives for its existing biotech assets.
- LightSolver's LPU platform targets a projected ~$89B HPC market by 2034, with customer validation including Boeing and other Tier-1 aerospace/defense entities.
- Commercial availability of the LPU platform is targeted for 2028.
- The filing is a 6-K furnishing a corporate presentation; no financial data, guidance, or binding deal terms are disclosed.
Financial Impact
No financial figures disclosed. $5M funding commitment to LightSolver at closing; warrant tranches tied to milestones.
Risk Factors
- No binding transaction terms or financial details disclosed; the acquisition structure and dilution remain unclear.
- LightSolver's technology is pre-commercial with a 2028 target; execution and market adoption risks are high.
- CollPlant's legacy biotech assets face an uncertain strategic review outcome.
- The company has a history of activist investor filings (Loewenbaum group SC 13D/A), adding governance uncertainty.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-101147 |
| Document: ea0305946-6k_collplant.htm | 0001213900-26-101147 |
| Document: 0001213900-26-101147-index-headers.html | 0001213900-26-101147 |
| Document: 0001213900-26-101147-index.html | 0001213900-26-101147 |
| Document: 0001213900-26-101147.txt | 0001213900-26-101147 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 144 | $3.78 | awaiting T+1 | — | $3.90 (+3.17%) |
Oct 19, 2026 8d ago | 3 | $3.88 $3.76 | ▼ −3.22% | ▼ −3.75% | $3.90 (+0.52%) |
Oct 15, 2026 12d ago | 6-K | $3.68 $3.63 | ▲ +1.49% | ▲ +0.39% | $3.90 (−5.98%) |
Oct 9, 2026 18d ago | 6-K | $4.02 $3.91 | ▲ +2.74% | ▲ +2.72% | $3.90 (+2.99%) |
Oct 8, 2026 19d ago | SC 13G | $3.97 $3.51 | ▼ −11.59% | ▼ −12.19% | $3.90 (−1.76%) |
Oct 8, 2026 19d ago | SC 13D/A | $3.97 $3.51 | ▼ −11.59% | ▼ −12.19% | $3.90 (−1.76%) |
Oct 6, 2026 21d ago | 6-K | $3.39 $3.46 | ▲ +2.06% | ▲ +2.30% | $3.90 (+15.04%) |
Sep 30, 2026 27d ago | 6-K | $3.57 $3.46 | ▲ +3.08% | ▲ +3.82% | $3.90 (−9.24%) |
Sep 30, 2026 27d ago | Press Release | $3.57 $3.46 | ▲ +3.08% | ▲ +3.82% | $3.90 (−9.24%) |
Sep 24, 2026 4w ago | 6-K | $4.12 $4.25 | ▲ +3.16% | ▲ +2.61% | $3.90 (−5.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers